BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 16960869)

  • 1. ABO incompatible stem cell transplantation in children does not influence outcome.
    Helming AM; Brand A; Wolterbeek R; van Tol MJ; Egeler RM; Ball LM
    Pediatr Blood Cancer; 2007 Sep; 49(3):313-7. PubMed ID: 16960869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
    Blin N; Traineau R; Houssin S; Peffault de Latour R; Petropoulou A; Robin M; Larghero J; Ribaud P; Socié G
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1315-23. PubMed ID: 20353831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
    Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
    Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
    Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
    Rowley SD; Liang PS; Ulz L
    Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
    Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
    Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?
    Gutiérrez-Aguirre CH; Gómez-De-León A; Alatorre-Ricardo J; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; Mancías-Guerra C; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2014 May; 54(5):1269-77. PubMed ID: 24898453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
    Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
    Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kobayashi T; Sato A; Iseki T; Yamaguchi T; Tojo A; Asano S
    Bone Marrow Transplant; 2007 Sep; 40(6):523-8. PubMed ID: 17646845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.
    Resnick IB; Tsirigotis PD; Shapira MY; Aker M; Bitan M; Samuel S; Abdul-Hai A; Ackerstein A; Or R; Slavin S
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):409-17. PubMed ID: 18342783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation.
    Remberger M; Watz E; Ringdén O; Mattsson J; Shanwell A; Wikman A
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):675-82. PubMed ID: 17531777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.